about
Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.Palliative care of bone pain due to skeletal metastases: Exploring newer avenues using neutron activated (45)Ca.Preparation of (99m)Tc carbonyl DTPA-bevacizumab and its bioevaluation in a melanoma model.Radiosynthesis and biological evaluation of 68Ga-labeled colchicine conjugates.Radiochemistry, pre-clinical studies and first clinical investigation of 90Y-labeled hydroxyapatite (HA) particles prepared utilizing 90Y produced by (n,γ) route.In Vitro Evaluation of 188Re-HEDP: A Mechanistic View of Bone Pain Palliations.Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.Preparation and preliminary bioevaluation of 99mTc(CO)3-11β-progesterone derivative prepared via click chemistry route.99mTc-labeling of colchicine using [99mTc(CO)3(H2O)3]+ and [99mTc triple bond N]2+ core for the preparation of potential tumor-targeting agents.Toward realization of 'mix-and-use' approach in ⁶⁸Ga radiopharmacy: preparation, evaluation and preliminary clinical utilization of ⁶⁸Ga-labeled NODAGA-coupled RGD peptide derivative.Magneto-thermally responsive hydrogels for bladder cancer treatment: Therapeutic efficacy and in vivo biodistribution.Preparation and in vitro evaluation of radioiodinated bakuchiol as an anti tumor agent.Radiolabeling and Preliminary Evaluation of Ga-68 Labeled NODAGA-Ubiquicidin Fragments for Prospective Infection Imaging.Preparation of 177Lu-labeled oxine in lipiodol as a possible agent for therapy of hepatocellular carcinoma: a preliminary animal study.Preparation and evaluation of 99mTc(CO)3-labeled pentadecanoic acid derivative and its suspension in lipiodol.(170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation.A novel [186/188Re]-labelled porphyrin for targeted radiotherapy.177Lu labelled polyaminophosphonates as potential agents for bone pain palliation.177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.Evaluation of 90Y-DTPA and 90Y-DOTA for potential application in intra-vascular radionuclide therapy.99mTc-labeling studies of a modified metronidazole and its biodistribution in tumor bearing animal models.Practicality of production of ³²P by direct neutron activation for its utilization in bone pain palliation as Na₃[³²P]PO₄.Synthesis and biological evaluation of 90Y-labeled porphyrin-DOTA conjugate: a potential molecule for targeted tumor therapy.Preparation of 166Ho-oxine-lipiodol and its preliminary bioevaluation for the potential application in therapy of liver cancer.Preparation and in-vivo evaluation of (188)Re(CO)(3)-colchicine complex for use as tumor-targeting agent.On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia.Synthesis and bio-evaluation of a new fatty acid derivative for myocardial imaging.A novel [99mTc[triple bond]N]2+ complex of metronidazole xanthate as a potential agent for targeting hypoxia.Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.Synthesis of 99mTc-nitrido heterocomplex of piperidine and in vitro and in vivo evaluation of its affinity for sigma receptors.99mTcN complexes of tert-butyl dithiocarbamate and methoxyisobutyl dithiocarbamate as myocardial and brain imaging agents.Preparation and preliminary biological evaluation of a (166)Ho labeled polyazamacrocycle for possible use as an intravascular brachytherapy (IVBT) agent.Preparation and in vivo evaluation of (99m)TcN-tertiary butyl xanthate as a potential myocardial agent.68Ga labeled Erlotinib: A novel PET probe for imaging EGFR over-expressing tumors.Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.99m Tc-labeled NGR-chlorambucil conjugate, 99m Tc-HYNIC-CLB-c(NGR) for targeted chemotherapy and molecular imaging.Radiochemical studies of 99mTc complexes of modified cysteine ligands and bifunctional chelating agents.A "mix-and-use" approach for formulation of human clinical doses of 177 Lu-DOTMP at hospital radiopharmacy for management of pain arising from skeletal metastases.Technetium-99m complexes of polydentate amine-pyrrole and amine-thiophene ligands.
P50
Q38773018-50FC50C4-16BC-4334-B0F8-B1E875C77431Q38908785-2603093C-4A83-4F96-ADBA-B6B377E8BB1CQ38974076-7D62BC95-2A07-49FA-805E-93441D6A489BQ38979189-ECC79661-B1CF-4F95-BE0C-D6A80C6E7A2FQ39042278-121CA250-E4EB-4A6C-9AF2-1048F8D30454Q39154510-E5EC8525-454A-4DD0-A25F-AAFE042F4E9FQ39198577-4FEBF9B2-5F13-4B1B-8F5B-0D446149C35BQ39635109-01623667-58D8-4B03-862B-5A868F1B07F4Q40350832-81A3E29E-8233-4244-AD41-E79624943D60Q40364269-ADEF28F5-C765-4CC3-96E8-9D0AF8642018Q40419981-3FE5ECFA-6D72-4314-8B17-9B6F136389A9Q40479326-0E04B729-7B08-4405-817A-3DDC6B681F08Q40616136-6A25D39C-56CA-49B5-8833-92121F9B2468Q42904768-BC1497CF-202A-44A3-9445-93A88E01AEA4Q43289074-D37FCD7A-EC49-4790-8118-8DB0889196AEQ43490156-256B6708-5BEB-42CF-AC95-6A219396C1F8Q43716968-5FF5FB9F-724D-440C-AD6A-A7BEA5ED4758Q43744948-56C78674-5059-491B-89F1-88355996E713Q43826942-4EC31485-279C-4342-BCF6-41E988893502Q44084138-4BA99A66-EED0-401D-AC3F-B2ADEB74CE17Q44118235-D06B8727-32F1-4FBD-ACCE-3A2831C335B5Q44353063-5B4EB182-6DDB-41D0-9C88-9B81570B9B18Q45257979-077FF0B2-9B95-400B-971D-E0EB030C1C7DQ46076542-7C1541C2-7D93-491B-AA47-E6207A669E00Q46090267-C8272CFF-6F85-49AF-8CA7-68BC37951ADCQ46181878-9085B3A4-D686-4AB6-A28E-C26C8E519224Q46386545-B343DE65-6A02-4738-9FF6-629738D7C029Q46431202-ED3A7689-AF14-46CD-850A-DA71CAFFCA8DQ46619351-88389C9E-6E69-4466-8E45-82161078B80EQ46677510-FCB21FD4-ECA4-4591-9250-C10D7541D4B4Q46735086-E43804A3-1EF7-4A13-86AE-2980A4DD5505Q46738474-B7D9AF0A-A816-4B9D-962F-34305B1CCC55Q46849636-E4493FB1-031D-49D3-A44C-33A936C5EDA4Q46911324-C0E869CA-2E2F-43D7-A612-58404E3AE90CQ47821706-D550A7E9-19AF-491C-B3D2-FC653CC4C7A1Q48015008-45012146-C429-47F2-BAA6-B99A48A5770DQ48091368-9D60085C-F257-4727-82AA-FFB2E75A7A77Q48120917-44B12ABD-6E57-407A-BC0B-35CB8EAC5D7AQ48182563-D47F2842-ACBA-4C54-B14B-03041ABFECA7Q48252721-419EC89C-8E8E-44D8-9882-DC435529C7C7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Haladhar Dev Sarma
@ast
Haladhar Dev Sarma
@en
Haladhar Dev Sarma
@es
Haladhar Dev Sarma
@nl
Haladhar Dev Sarma
@sl
type
label
Haladhar Dev Sarma
@ast
Haladhar Dev Sarma
@en
Haladhar Dev Sarma
@es
Haladhar Dev Sarma
@nl
Haladhar Dev Sarma
@sl
altLabel
Sarma H D
@en
prefLabel
Haladhar Dev Sarma
@ast
Haladhar Dev Sarma
@en
Haladhar Dev Sarma
@es
Haladhar Dev Sarma
@nl
Haladhar Dev Sarma
@sl
P1053
C-2350-2009
P106
P1153
35547449300
P2038
Haladhar_Dev_Sarma
P31
P3829
P3835
haladhar-dev-sarma
P4012
P496
0000-0001-7168-4487
P569
2000-01-01T00:00:00Z